Real-life use of apremilast for the treatment of psoriasis in patients with oncological comorbidities: a retrospective descriptive multicentre study in France

Podevin, Pauline; Cottencin, A.-C.; Becquart, C.; Azib, S.; Duparc, Adeline; Darras, S.; Florin, V.; Faiz, Sarah; Lehembre, S. Duvert; Staumont‐Sallé, D.; Dezoteux, F.

doi:10.1684/ejd.2023.4407

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to its broad cellular targets and relative tolerability, apremilast has been investigated for its efficacy in chronic inflammatory diseases, including AD and different psoriasis variants ( 15 ). In a recent report documenting the real-life utilization of apremilast in patients diagnosed with both psoriasis and cancer, apremilast demonstrated an improvement in quality of life, while maintaining a favorable safety profile ( 16 , 17 ). Our cases demonstrated the effectiveness of apremilast in achieving remission and maintaining stability without recurrence.…”

Section: Discussionmentioning

confidence: 99%

Case report: Treatment of psoriasiform dermatitis in patients with malignancy

Mao,

Du,

Jia

et al. 2024

Front. Med.

View full text Add to dashboard Cite

Psoriasis and atopic dermatitis (AD) are prevalent inflammatory skin disorders, each stemming from diverse factors, and characterized by recurring episodes. In certain complex cases, the clinical and pathological features exhibit overlapping and atypical characteristics, making accurate clinical diagnosis and targeted treatment a challenge. Psoriasiform dermatitis is the term used to describe such cases. Moreover, when patients have a history of malignancy, the situation becomes even more intricate, resulting in limited treatment options. Biologic therapies have transformed the management of immune-mediated inflammatory diseases, including psoriasis and AD. Meanwhile, the safety of biologics in special populations, especially among patients with a history of malignancy, should be underlined. The selective Janus kinase 1 (JAK1) inhibitor abrocitinib has been approved for the treatment of AD and has showed satisfying efficacy and safety in the treatment of psoriasis in clinical trials. Although unreported, JAK1 inhibitors are thought to have the potential to increase the risk of potential tumors. Apremilast, an oral phosphodiesterase (PDE)-4 inhibitor, is approved for moderate to severe plaque psoriasis. It has been investigated for its efficacy in AD, and is not contraindicated in malignancy. This report presents three cases of psoriasiform dermatitis in patients with a history of malignancy, showcasing significant improvement following treatment with systemic glucocorticoid, abrocitinib, or apremilast.

show abstract

Section: Discussionmentioning

confidence: 99%

Case report: Treatment of psoriasiform dermatitis in patients with malignancy

Mao,

Du,

Jia

et al. 2024

Front. Med.

View full text Add to dashboard Cite

show abstract

Apremilast in Patients Difficult to Treat: A Multicentric Real‐Life Long‐Term Experience

Trovato,

Capalbo,

Cartocci

et al. 2023

Dermatologic Therapy

View full text Add to dashboard Cite

Psoriasis is an inflammatory disease nowadays considered not only as a cutaneous but also as a systemic disease. Systemic therapy plays a crucial role in the management of psoriasis. Apremilast is an inhibitor of phosphodiesterase-4 (PDE4), indicated in the treatment of moderate-to-severe psoriasis. Here, we report a multicentric case series of patients treated with apremilast with resolution of skin manifestations and maintenance of clinical response for a minimum of 2 years. By inhibiting PDE4, apremilast acts as a ubiquitous intracellular enzyme, whose active form degrades adenosine cyclic intracellular monophosphate (cAMP) into AMP. The increase in cAMP determines a decrease in proinflammatory cytokines such as TNF-a, IL-17, IL-23, and upregulation of IL-10 with an anti-inflammatory action. Considering the growing incidence of comorbidities in the world population and in particular the strict correlation in patients with psoriasis, it is important to identify therapeutic options able to avoid a negative impact on patients with both conditions. The aim of this work is to highlight the utility of this molecule in the long-term management of these patients. Moreover, these case series further underline the high safety profile and manageability of this small molecule.

show abstract

Real-life use of apremilast for the treatment of psoriasis in patients with oncological comorbidities: a retrospective descriptive multicentre study in France

Cited by 2 publications

References 0 publications

Case report: Treatment of psoriasiform dermatitis in patients with malignancy

Case report: Treatment of psoriasiform dermatitis in patients with malignancy

Apremilast in Patients Difficult to Treat: A Multicentric Real‐Life Long‐Term Experience

Contact Info

Product

Resources

About